EA
ACAD icon

Emerald Advisers’s Acadia Pharmaceuticals ACAD Stock Holding History

Emerald Advisers’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-28,637
Closed -$637K – 238
2026
Q1 		$637K Sell
28,637
-782,560
-96% -$18.7M 0.02% 162
2025
Q4 		$21.7M Buy
811,197
+241,526
+42% +$5.77M 0.67% 68
2025
Q3 		$12.2M Sell
569,671
-22,687
-4% -$537K 0.39% 96
2025
Q2 		$12.8M Sell
592,358
-223,547
-27% -$4.16M 0.47% 83
2025
Q1 		$13.6M Sell
815,905
-9,164
-1% -$166K 0.61% 66
2024
Q4 		$15.1M Sell
825,069
-5,760
-0.7% -$93K 0.59% 69
2024
Q3 		$12.8M Buy
830,829
+21,998
+3% +$367K 0.49% 79
2024
Q2 		$13.1M Sell
808,831
-842,293
-51% -$13.6M 0.55% 67
2024
Q1 		$30.5M Buy
1,651,124
+5,559
+0.3% +$138K 1.23% 21
2023
Q4 		$51.5M Sell
1,645,565
-35,487
-2% -$847K 2.21% 2
2023
Q3 		$35M Buy
1,681,052
+64,100
+4% +$1.74M 1.7% 8
2023
Q2 		$38.7M Buy
1,616,952
+120,392
+8% +$2.68M 1.69% 4
2023
Q1 		$28.2M Buy
1,496,560
+174,414
+13% +$3.32M 1.35% 15
2022
Q4 		$21M Sell
1,322,146
-7,480
-0.6% -$117K 1.02% 41
2022
Q3 		$21.8M Buy
1,329,626
+468,877
+54% +$7.59M 1.12% 29
2022
Q2 		$12.1M Buy
860,749
+72,011
+9% +$1.34M 0.62% 67
2022
Q1 		$19.1M Buy
788,738
+71,420
+10% +$1.73M 0.73% 60
2021
Q4 		$16.7M Buy
+717,318
New +$14.4M 0.62% 68

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Emerald Advisers's ACAD Position: Q2 2026 in Review

Emerald Advisers sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 28,637 shares — an estimated $637K sold.

Emerald Advisers first reported a position in ACAD in Q4 2021 and held it in 18 quarters. The position peaked at $51.5M in Q4 2023. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Emerald Advisers reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Emerald Advisers sold 28,637 Acadia Pharmaceuticals shares in Q2 2026, an estimated $637K.
  • Emerald Advisers first reported a position in Acadia Pharmaceuticals in Q4 2021 and held it in 18 quarters.
  • Emerald Advisers's Acadia Pharmaceuticals position peaked at $51.5M in Q4 2023.
  • 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Emerald Advisers's 13F filing for Q2 2026, filed 5 Aug 2026.